

InterSystems and Oncodesign partner for the optimization of data use to enhance and accelerate Drug Discovery processes in oncology

As part of this new long-term partnership, Oncodesign will use the InterSystems IRIS for Health™ solution to organize and leverage healthcare data to accelerate the search for new treatments in oncology using Artificial Intelligence (AI).

Paris, May 18th, 2021 - [InterSystems](#), a leader in healthcare data management, and [Oncodesign](#), a biopharmaceutical company specializing in precision medicine, today announced the signing of a strategic partnership aimed at advancing research for new treatments in the field of oncology.

In a context characterized by an exponential growth of data volumes over the last 20 years, the quality and use of health and research data have become two critical issues for all healthcare stakeholders. The current health crisis has only reinforced the importance of an agile and decompartmentalized strategy for health data governance.

As part of this partnership, Oncodesign has chosen to combine its proprietary platform for the identification and validation of new therapeutic targets, called OncoSNIPER, with InterSystems' unified health data management platform, known as InterSystems IRIS for Health. This alliance will allow both companies to develop and optimize essential synergies between the two platforms.

The [InterSystems IRIS for Health](#) data platform will be integrated into Oncodesign's recently established Artificial Intelligence (AI) Business Unit for the storage and management of various preclinical and clinical data sources, which are highly valuable to each of the businesses involved in the drug discovery process. By analyzing and better exploiting the data consolidated through **InterSystems IRIS for Health**, Oncodesign's AI BU will optimize the development of **OncoSNIPER**, notably through more accurate functioning of its algorithms. In addition, InterSystems will provide Oncodesign with the benefit of its international network of strategic academic partners generating health data (hospitals and universities), particularly in North America.

For **InterSystems**, this partnership is part of a strategic approach to healthcare players through its access to Oncodesign's solid expertise in drug discovery and reflects its historical commitment to oncology. With a solid domestic network, InterSystems has been working for many years with major cancer centers (known as CLCC in France) through its patient administrative and clinical management solution, [InterSystems TrakCare](#) (especially in Dijon, Nice and Reims), as well as with the Toulouse University Cancer Institute - Oncopole (IUCT-O) with [InterSystems HealthShare](#), for comprehensive patient management and better coordination of the various private and public players in the region. The company has also made its expertise in health data exploitation available to innovative partners such as the start-up [MyPL](#) and the [Guerbet Group](#).

For **Michel Amous, Regional Director EMEA at InterSystems**: *"We are delighted to begin this partnership with Oncodesign, which has been a major player in the biotechnology industry for 25 years. Our goal is to provide them with our expertise in optimizing data platforms to build a new intelligent architecture for oncology research. The pooling of health data - scattered, heterogeneous but so valuable - is not just a simple operational consolidation. It is a project with strategic scope aimed at aggregating the various sources of data available to Oncodesign in order to improve communication between them. This dynamic governance will enable Oncodesign to remain at the forefront of biopharmaceutical innovation and ultimately to commercialize new therapeutic solutions to better serve the public interest. "*

For **Oncodesign**, this partnership is the second step in its strategic development based around AI after the launch in 2017 of the OncoSNIPER project (clinical trial of 600 patients with 3 oncology indications and 16 partners). After generating large amounts of heterogeneous clinical data, the company needs to structure the available data using the InterSystems IRIS for Health data platform, before implementing the algorithms needed to select sub-populations of patients with treatment-resistant cancers.

Philippe Genne, Chairman and CEO of Oncodesign, stated: *"We have known the InterSystems teams well for several years, and we are therefore very pleased to formalize our collaboration through this ambitious partnership. Our expertise at Oncodesign is in developing new treatments and InterSystems' is in leveraging data to accelerate the digital transformation of companies. Together, we will be able to pool our respective fields of expertise in order to make our drug discovery process in precision medicine more reliable and even faster. Traditionally, the lead optimization phase alone can last up to 3 years and cost between 10 and 12 million euros with random results in the medium term (1/10 success rate). Today, artificial intelligence is changing the game: the exploitation of data gives us the possibility to make more informed choices in increasingly rapid timeframes. "*

This collaboration will bring together several distinct and complementary fields of expertise, including data science, artificial intelligence, pharmacology, chemistry, biology and clinical research. The two companies share a common goal: to **harness the power of data to develop and industrialize new therapeutic solutions in the field of oncology.**

On **May 21st** next, Oncodesign will inaugurate its new headquarters in **Dijon** (Bâtiment Jean Mermoz - 18 rue Jean Mazen), which will house its AI teams. On the same day, the company will also launch its new development strategy based on AI approaches.

[About InterSystems](#)

Established in 1978, InterSystems is the leading provider of data technology for extremely critical data in the healthcare, finance, and logistics sectors. Its cloud-first data platforms solve interoperability, speed, and scalability problems for large organizations around the globe. InterSystems also develops and supports unique managed services for hospital EMRs, unified care records for communities and nations, and laboratory information management systems. InterSystems is committed to excellence through its award-winning, 24x7 support for customers and partners in more than 80 countries. Privately held and headquartered in Cambridge, Massachusetts, InterSystems has 25 offices worldwide. For more information, please visit [InterSystems.com](https://www.inter-systems.com).

About Oncodesign

Founded 25 years ago by Dr. Philippe Genne, the Company's CEO and Chairman, Oncodesign is a biopharmaceutical company dedicated to precision medicine. With its unique experience acquired by working with more than 800 clients, including the world's largest pharmaceutical companies, along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, pharmacology, regulated bioanalysis, medical imaging and Artificial Intelligence, Oncodesign is able to predict and identify, at a very early stage, each molecule's therapeutic usefulness and potential to become an effective drug. Applied to kinase inhibitors, which represent a market estimated at over \$65 billion by 2027 and accounting for almost 25% of the pharmaceutical industry's R&D expenditure, Oncodesign's technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Servier. Oncodesign is based in Dijon, France, in the heart of the town's university and hospital hub, and within the Paris-Saclay cluster. Oncodesign has 233 employees and subsidiaries in Canada and the USA.

www.oncodesign.com

InterSystems Contacts

InterSystems

Michel Amous
Regional Managing Director EMEA
Tel. : +33 (0)1 77 49 16 00

Communication-France@intersystems.com

Edelman

Media Relations
Dominic Riding
Tel : +33 (0)7 77 96 24 42

InterSystemsFrance@edelman.com

Oncodesign Contacts

Oncodesign

Philippe Genne
CEO
Tel. : +33 (0)3 80 78 82 60
investisseurs@oncodesign.com

NewCap

Investor Relations
Mathilde Bohin / Louis-Victor Delouvrier
Tel. : +33 (0)1 44 71 94 95
oncodesign@newcap.eu

NewCap

Media Relations
Arthur Rouillé
Tel. : +33 (0)1 44 71 00 15
oncodesign@newcap.eu